

Prescriber Criteria Form

Cabometyx 2026 PA Fax 1367-A v2 010126.docx

Cabometyx (cabozantinib)

Coverage Determination

This fax machine is located in a secure location as required by HIPAA regulations.

Complete/review information, sign and date. Fax signed forms to CVS Caremark at **1-855-633-7673**. Please contact CVS Caremark at **1-866-785-5714** with questions regarding the prior authorization process. When conditions are met, we will authorize the coverage of Cabometyx (cabozantinib).

Drug Name:
Cabometyx (cabozantinib)

Patient Name:

Patient ID:

Patient DOB:

Patient Phone:

Prescriber Name:

Prescriber Address:

City:

State:

Zip:

Prescriber Phone:

Prescriber Fax:

Diagnosis:

ICD Code(s):

Please circle the appropriate answer for each question.

1	Does the patient have a diagnosis of renal cell carcinoma? [If no, then skip to question 3.]	Yes	No
2	Is the disease advanced, relapsed, or stage IV (including brain metastases)? [No further questions.]	Yes	No
3	Does the patient have a diagnosis of non-small cell lung cancer? [If no, then skip to question 6.]	Yes	No
4	Is the disease rearranged during transfection (RET)-positive? [If no, then no further questions.]	Yes	No
5	Is the disease recurrent, advanced, or metastatic? [No further questions.]	Yes	No
6	Does the patient have a diagnosis of hepatocellular carcinoma? [If no, then skip to question 8.]	Yes	No
7	Will the requested drug be used as subsequent therapy? [No further questions.]	Yes	No
8	Does the patient have a diagnosis of gastrointestinal stromal tumor (GIST)? [If no, then skip to question 11.]	Yes	No

9	Is the disease residual, unresectable, recurrent, or metastatic/tumor rupture? [If no, then no further questions.]	Yes	No
10	Has the disease progressed after at least two Food and Drug Administration (FDA)-approved therapies (for example, imatinib, sunitinib, regorafenib, ripretinib)? [No further questions.]	Yes	No
11	Does the patient have a diagnosis of Ewing sarcoma or osteosarcoma? [If no, then skip to question 13.]	Yes	No
12	Will the requested drug be used as subsequent therapy? [No further questions.]	Yes	No
13	Does the patient have a diagnosis of endometrial cancer? [If no, then skip to question 16.]	Yes	No
14	Is the disease recurrent? [If no, then no further questions.]	Yes	No
15	Will the requested drug be used as subsequent therapy? [No further questions.]	Yes	No
16	Does the patient have a diagnosis of locally advanced or metastatic differentiated thyroid cancer (DTC) (follicular, papillary, or oncocytic)? [If no, then skip to question 19.]	Yes	No
17	Has the disease progressed following a prior vascular endothelial growth factor receptor (VEGFR)- targeted therapy? [If no, then no further questions.]	Yes	No
18	Does the patient meet one of the following: A) the patient is refractory to radioactive iodine therapy (RAI), B) the patient is ineligible for RAI? [No further questions.]	Yes	No
19	Does the patient have a diagnosis of soft tissue sarcoma (alveolar soft part sarcoma or extraskeletal myxoid chondrosarcoma subtypes)? [If yes, then no further questions.]	Yes	No
20	Does the patient have a diagnosis of any of the following: A) pancreatic neuroendocrine tumors (pNET), B) extra-pancreatic neuroendocrine tumors (epNET)?	Yes	No

Comments:	_____
-----------	-------

By signing this form, I attest that the information provided is accurate and true as of this date and that the documentation supporting this information is available for review if requested by the health plan.

Prescriber (or Authorized) Signature: _____	Date: _____
---	-------------